Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FACT: Zybrestat + Chemo in Anaplastic Thyroid Carcinoma
NCT00507429Phase 3Terminated
- Sponsor
- Oncotelic Therapeutics, Inc.
- Start
- Aug 2007
- Primary completion
- Oct 2011
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial of fosbretabulin in anaplastic thyroid carcinoma (ATC) (2 arms), sponsored by Oncotelic Therapeutics, Inc. Primary endpoint: Overall Survival. Started Aug 2007; status: terminated.
02
Drugs
fosbretabulin
03
Conditions
anaplastic thyroid carcinoma (ATC)
Beyond the preview
Go deeper on NCT00507429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00507429.